Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Investing.com -- Bright Minds Biosciences (NASDAQ:DRUG) stock rose 5% after the clinical-stage biotechnology company announced positive topline results from its Phase 2 BREAKTHROUGH trial for BMB-101 ...

They also observed that these non-convulsive seizures were much more frequent than convulsive seizures, occurring hundreds of times each day in some mice. That's when Paz reached out to Cilio, an ...

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

Epilepsy is not a one size fits all condition and there are a few tell tale signs that parents could miss, said Dr Jonathan Redelinghuys.

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...